News

FDA strengthens kidney warnings on two diabetes drugs


 

References

The Food and Drug Administration has revised warnings on certain medications for type 2 diabetes mellitus based on recent reports of kidney injury. The warning labels on canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) now include recommendations on ways to minimize the risk and more information on kidney injury.

“From March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use,” the FDA statement said.

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

The FDA went on to note: “Health care professionals should consider factors that may predispose patients to acute kidney injury prior to starting them on canagliflozin or dapagliflozin. These include decreased blood volume; chronic kidney insufficiency; congestive heart failure; and taking other medications such as diuretics, blood pressure medicines called angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Assess kidney function prior to starting canagliflozin or dapagliflozin and monitor periodically thereafter. If acute kidney injury occurs, promptly discontinue the drug and treat the kidney impairment.”

acruz@frontlinemedcom.com

Recommended Reading

FDA: CT scans safe for patients with electronic medical devices
MDedge Cardiology
VIDEO: New ACC consensus guidance addresses nonstatin therapies
MDedge Cardiology
FDA adds safety warnings to certain type 2 diabetes medications
MDedge Cardiology
Ticagrelor cuts post-MI events in diabetes patients
MDedge Cardiology
New analysis bolsters metformin as first line in type 2 diabetes
MDedge Cardiology
STAMPEDE: Metabolic surgery bests medical therapy long term
MDedge Cardiology
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
MDedge Cardiology
Sitagliptin does not reduce liver fat in NAFLD
MDedge Cardiology
Strong gender difference for stroke in diabetes patients with restless legs syndrome
MDedge Cardiology
Strong gender difference for stroke in diabetes patients with restless legs syndrome
MDedge Cardiology